Fig. 1From: Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanomaGeneral Kaplan-Meier survival curves – Overall patient survival (a) as of February 17th 2017, PFS by immune-related (irRC) (b) criteria. Censored data are shown as open boxes on graphsBack to article page